Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: Results of therapy and correlates of response

Journal of Clinical Oncology

Volumn 22, Issue 13, 2004, Pages 2662-2670

  Levine, Alexandra M ^a   Tulpule, Anil ^a   Espina, Byron ^a   Sherrod, Andy ^a   Boswell, William D ^a   Lieberman, Robert D ^a   Nathwani, Bharat N ^a   Welles, Lauri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CHOP PROTOCOL; GLYCOPROTEIN P; LIPOSOME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE COUNT; MULTIDRUG RESISTANCE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; BIOSYNTHESIS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SURVIVAL; VIRUS LOAD;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4 LYMPHOCYTE COUNT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; LIPOSOMES; LYMPHOMA, AIDS-RELATED; P-GLYCOPROTEIN; PREDNISONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE; VIRAL LOAD;

EID: 4344653008     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.093     Document Type: Article

References (39)

1. Levine AM, Wernz JC, Kaplan L, et al: Low dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS related lymphoma: A prospective multi-institutional trial. JAMA 266:84-88, 1991
2. Kaplan LD, Straus DJ, Testa MA, et al: Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 336:1641-1648, 1997
3. Sparano JA, Wiernik PH, Hu X, et al: Pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus associated non-Hodgkin's lymphoma. J Clin Oncol 14:3026-3035, 1996
4. Gisselbrecht C, Oksenhendler E, Tirelli U, et al: Human immunodeficiency virus related lymphoma treatment with intensive combination chemotherapy. Am J Med 95:188-196, 1993
5. Besson C, Gouybar A, Gabarre J, et al: Changes in AIDS related lymphoma since the era of highly active antiretroviral therapy. Blood 98:2339-2344, 2001
6. Antinori A, Cingolani A, Alba L, et al: Better response to chemotherapy and prolonged survival in AIDS related lymphomas responding to highly active antiretroviral therapy. AIDS 15:1483-1491, 2001
7. Hoffmann C, Wolf E, Fatkenheuer G, et al: Response to highly active anti-retroviral therapy strongly predicts outcome in patients with AIDS related lymphoma. AIDS 17:1521-1529, 2003
8. Palella FJ, Delaney KM, Moorman AC, et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:653-660, 1998
9. Mocroft A, Ledergerber B, Katlama B, et al: Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 362:22-29, 2003
10. Ueda K, Coswell MM, Gottesman MM, et al: The mdr1 gene, responsible for multidrug-resistance, codes for p-glycoprotein. Biochem Biophys Res Commun 141:956-962, 1986
11. Pastan I, Gottesman MM: Multidrug resistance. Annu Rev Med 42:277-286, 1991
12. Horio M, Gottesman MM, Pastan I: ATP dependent transport of vinblastine in vesicles from human multidrug-resistance cells. Proc Natl Acad Sci U S A 85:3580-3584, 1988
13. Hamada H, Tsuruo T: Purification of the 170 to 180 kilodalton membrane glycoprotein associated with multidrug resistance. J Biol Chem 263:1454-1458, 1988
14. Yuen AR, Sikic BI: Multidrug resistance in lymphoma. J Clin Oncol 12:2453-2459, 1994
15. Miller TP, Grogan TM, Dalton WS, et al: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Oncol 9:17-24, 1991
16. Gascoyne R, Tolcher A, Van Inderstine EM, et al: The prognostic relevance of glycoprotein expression in malignant lymphomas. Proceedings of the General Motors Cancer Res Foundation International Symposium, Toronto, Canada, 1993 (abstract A7)
17. Tulpule A, Sherrod A, Dharmapala D, et al: Multidrug resistance (MDR-1) expression in AIDS related lymphomas. Leuk Res 26:121-127, 2002
18. Conley BA, Egorin MJ, Whitacre MT. et al: Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. Cancer Chemother Pharmacol 33:107-112, 1993
19. Cowens JW, Creaven PJ, Greco WR, et al: Initial clinical (Phase I) trial of Myocet (doxorubicin encapsulated in liposomes). Cancer Res 53:2796-2802, 1993
20. Batist G, Ramakrishnan G, Rao CS, et al: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444-1454, 2001
21. Rahman A, Husain SR, Siddiqui J, et al: Liposome mediated modulation of multidrug resistance in human HL-60 leukemia cells. J Natl Cancer Inst 84:1909-1915, 1992
22. Thierry AR, Vige D, Coughlin SS, et al: Modulation of doxorubicin resistance in multidrug resistant cells by liposomes. FASEB J 7:572-579, 1993
23. McKelvey EM, Gottlieb JA, Wilson HE, et al: Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493, 1976
24. Schlaifer D, Laurent G, Chittal S, et al: Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancer. Br J Cancer 62:177-178, 1990
25. Pileri S, Sabattinni E, Falini B, et al: Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 19:131-140, 1991
26. Mehta CR, Patel NR: A network algorithm for performing Fisher's exact test in r × c contingency tables. J Am Stat Assoc 78:427-434, 1983
27. Kalbfliesch JD, Prentice RI: The statistical analysis of failure time data. New York, NY, John Wiley and Sons, 1980
28. Tarone RE, Ware J: On distribution-free tests for equality of survival distributions. Biometrika 64:156-160, 1977
29. International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
30. Lee CG, Gottesman MM, Cardarelli CO, et al: HIV-1 protease inhibitors are substrates for the MDR-1 multidrug transporter. Biochemistry 37:3594-3601, 1998
31. Kim RB, Fromm MF, Wandel C, et al: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294, 1998
32. Fellay J, Marzolini C, Meaden ER, et al: Response to antiretroviral treatment in HIV-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 359:30-36, 2002
33. Chandler B, Almond L, Ford J, et al: The effects of protease inhibitors and non-nucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 33:551-556, 2003
34. Little RF, Pittaluga S, Grant IM, et al: Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose adjusted EPOCH: Impact of antiretroviral therapy suspension and tumor biology. Blood 101:4653-4659, 2003
35. Levine AM, Seneviratne L, Espina BM, et al: Evolving characteristics of AIDS related lymphomas. Blood 96:4084-4090, 2000
36. Matthews GV, Bower M, Mandalia S, et al: Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 96:2730-2734, 2000
37. Ratner L, Lee J, Tang S, et al: Chemotherapy for HIV associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19:2171-2178, 2001
38. Vaccher E, Tirelli U, Spina M, et al: Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus related non-Hodgkin's lymphomas: A single institute study of 96 patients. J Clin Oncol 14:2217-2223, 1996
39. Rossi G, Donisi A, Casari S, et al: The International Prognostic Index can be used as a guide to treatment decision regarding patients with HIV related non-Hodgkin's lymphoma. Cancer 86:2391-2397, 1999